Published in Ann Rheum Dis on January 24, 2007
Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis | NCT01722214
Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest (2008) 3.90
Molecular mechanisms and clinical implications of reversible protein S-glutathionylation. Antioxid Redox Signal (2008) 2.67
Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum (2009) 1.56
Oxidized LDL: diversity, patterns of recognition, and pathophysiology. Antioxid Redox Signal (2010) 1.47
Cardiovascular co-morbidity in rheumatic diseases. Vasc Health Risk Manag (2008) 1.16
Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers. Ann Rheum Dis (2013) 1.07
Vascular effects of biologic agents in RA and spondyloarthropathies. Nat Rev Rheumatol (2009) 1.04
The role of endothelial function and its assessment in rheumatoid arthritis. Nat Rev Rheumatol (2010) 1.01
MyD88-dependent interplay between myeloid and endothelial cells in the initiation and progression of obesity-associated inflammatory diseases. J Exp Med (2014) 0.98
Infliximab improves vascular stiffness in patients with rheumatoid arthritis. Ann Rheum Dis (2008) 0.96
Vascular function and inflammation in rheumatoid arthritis: the role of physical activity. Open Cardiovasc Med J (2010) 0.94
Cardiovascular safety of biologic therapies for the treatment of RA. Nat Rev Rheumatol (2011) 0.92
Hepatic steatosis, carotid plaques and achieving MDA in psoriatic arthritis patients starting TNF-α blockers treatment: a prospective study. Arthritis Res Ther (2012) 0.90
Kruppel-like factor 15 is critical for vascular inflammation. J Clin Invest (2013) 0.87
Causes of death in patients with rheumatoid arthritis autopsied during a 40-year period. Rheumatol Int (2008) 0.87
Psoriasis and new-onset diabetes: a Danish nationwide cohort study. Diabetes Care (2013) 0.86
Protein glutathionylation in cardiovascular diseases. Int J Mol Sci (2013) 0.83
Unresolved questions in rheumatology: motion for debate: the data support evidence-based management recommendations for cardiovascular disease in rheumatoid arthritis. Arthritis Rheum (2013) 0.83
Cardiovascular disease and rheumatoid arthritis: an update. Curr Rheumatol Rep (2012) 0.81
Targeting Low Disease Activity in Elderly-Onset Rheumatoid Arthritis: Current and Future Roles of Biological Disease-Modifying Antirheumatic Drugs. Drugs Aging (2016) 0.79
Eleutheroside E ameliorates arthritis severity in collagen-induced arthritis mice model by suppressing inflammatory cytokine release. Inflammation (2014) 0.79
Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. Ann Rheum Dis (2017) 0.75
Cardiovascular risk management in patients with inflammatory arthritis: what is good for the joint is good for the heart and vice versa! F1000 Med Rep (2010) 0.75
New and emerging therapies for the treatment of rheumatoid arthritis. Open Access Rheumatol (2010) 0.75
Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Open Access Rheumatol (2009) 0.75
Microvesicles Derived from Inflammation-Challenged Endothelial Cells Modulate Vascular Smooth Muscle Cell Functions. Front Physiol (2017) 0.75
Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis: a cohort study. Rheumatol Int (2017) 0.75
Impact of 24 months of anti-TNF therapy versus methotrexate on body weight in patients with rheumatoid arthritis: a prospective observational study. Clin Rheumatol (2016) 0.75
Inflammation in atherosclerosis. Nature (2002) 28.92
Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum (1995) 26.94
Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol (2000) 14.59
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum (2003) 8.50
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med (1999) 6.84
Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med (1990) 5.65
Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum (2005) 5.31
Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum (2005) 4.63
Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation (2003) 4.52
Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford) (2005) 3.56
Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum (2002) 3.53
Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med (2004) 3.36
Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation (2004) 3.30
Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation (2004) 2.90
Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol (2006) 2.80
The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum (2005) 2.74
Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation (2006) 2.70
Tackling ischaemic heart disease in rheumatoid arthritis. Rheumatology (Oxford) (2003) 2.54
All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol (2003) 2.52
Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation (2002) 2.45
The many faces of tumor necrosis factor in stroke. Nat Med (2002) 2.33
Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum (2004) 2.32
Effect of anti TNFalpha therapy on arterial diameter and wall shear stress and HDL cholesterol. Atherosclerosis (2004) 2.30
Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc Natl Acad Sci U S A (2000) 2.25
Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol (2005) 2.17
Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum (2005) 2.14
Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Ann Rheum Dis (2005) 2.11
Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile. Arthritis Rheum (2001) 2.08
Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol (2003) 2.07
Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res (2005) 2.06
Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol (1998) 2.00
Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis Rheum (2006) 1.99
Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture. Curr Vasc Pharmacol (2005) 1.97
Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum (2006) 1.95
Stress-activated cytokines and the heart: from adaptation to maladaptation. Annu Rev Physiol (2002) 1.92
Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis (2003) 1.91
Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine (Baltimore) (2003) 1.75
Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis (2004) 1.73
Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology (Oxford) (2001) 1.63
Decreasing mortality in patients with rheumatoid arthritis: results from a large population based cohort in Sweden, 1964-95. J Rheumatol (2002) 1.56
Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis (2004) 1.54
Arterial stiffness in chronic inflammatory diseases. Hypertension (2005) 1.53
Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. Arthritis Rheum (2002) 1.52
Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis. Arthritis Rheum (2006) 1.51
Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med (2003) 1.51
Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther (2005) 1.39
Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum (2006) 1.38
The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis. Best Pract Res Clin Rheumatol (2004) 1.26
Effect of anti-tumor necrosis factor alpha therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis. Arthritis Rheum (2006) 1.24
Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol (2005) 1.22
Cytokines and hemostasis. Haematologica (2000) 1.17
Inflammation, thrombosis and acute coronary syndromes. Diab Vasc Dis Res (2005) 1.12
Tumour necrosis factor-alpha and the failing heart--pathophysiology and therapeutic implications. Basic Res Cardiol (2003) 1.12
Rheumatoid arthritis and macrovascular disease. Rheumatology (Oxford) (2003) 1.11
Arterial stiffness and central blood pressure, as determined by pulse wave analysis, in rheumatoid arthritis. Ann Rheum Dis (2003) 1.09
Hemostatic factors and cardiovascular disease in active rheumatoid arthritis: an 8 year followup study. J Rheumatol (2000) 1.03
Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis. Clin Chim Acta (2005) 0.99
Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis. Rheumatology (Oxford) (2005) 0.95
Lipoprotein(a) and lipids in relation to inflammation in rheumatoid arthritis. Clin Rheumatol (2000) 0.93
Synthesis of TNF alpha and TGF beta mRNA in the different micro-environments within atheromatous plaques. Cardiovasc Res (1996) 0.93
The role of endothelial cell dysfunction in the cardiovascular mortality of RA. Int Rev Immunol (2002) 0.91
Proinflammatory cytokine expression contributes to brain injury provoked by chronic monocyte activation. Mol Med (2001) 0.88
Therapeutic potential of TACE inhibitors in stroke. Curr Drug Targets CNS Neurol Disord (2005) 0.83
Methotrexate treatment and mortality in rheumatoid arthritis. Lancet (2002) 0.79
EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis (2009) 5.82
Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum (2006) 4.20
Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) (2006) 3.73
Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum (2007) 3.34
Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum (2003) 2.97
Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis (2009) 2.65
Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum (2007) 2.46
Classification criteria for rheumatoid arthritis--time to abandon rheumatoid factor? Rheumatology (Oxford) (2007) 2.15
Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis (2008) 2.01
Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology (Oxford) (2008) 1.91
Beneficial effects of a 3-week course of intramuscular glucocorticoid injections in patients with very early inflammatory polyarthritis: results of the STIVEA trial. Ann Rheum Dis (2009) 1.63
Low back pain in schoolchildren: the role of mechanical and psychosocial factors. Arch Dis Child (2003) 1.61
Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: results from the Norfolk Arthritis Register Study, a large inception cohort. Arthritis Rheum (2002) 1.58
Erosions in inflammatory polyarthritis are symmetrical regardless of rheumatoid factor status: results from a primary care-based inception cohort of patients. Rheumatology (Oxford) (2002) 1.53
Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken) (2010) 1.44
Five-year outcome of a primary-care-based inception cohort of patients with inflammatory polyarthritis plus psoriasis. Rheumatology (Oxford) (2007) 1.39
The role of anti-tumor necrosis factor receptor agents in cancer survivors: does the risk justify the benefit? Semin Oncol (2010) 1.38
Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis (2008) 1.32
European biologicals registers: methodology, selected results and perspectives. Ann Rheum Dis (2008) 1.31
Musculoskeletal pain is more generalised among people from ethnic minorities than among white people in Greater Manchester. Ann Rheum Dis (2002) 1.27
The British Society for Rheumatology Biologics Register: 6 years on. Rheumatology (Oxford) (2008) 1.22
Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis (2011) 1.17
Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis (2004) 1.14
Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis (2010) 1.13
Mortality trends in patients with early rheumatoid arthritis over 20 years: results from the Norfolk Arthritis Register. Arthritis Care Res (Hoboken) (2014) 1.08
Vitamin C and the risk of developing inflammatory polyarthritis: prospective nested case-control study. Ann Rheum Dis (2004) 1.07
Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. Ann Rheum Dis (2008) 1.05
The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis. Qual Life Res (2009) 0.99
Total costs and predictors of costs in individuals with early inflammatory polyarthritis: a community-based prospective study. Rheumatology (Oxford) (2002) 0.97
Can clinical factors at presentation be used to predict outcome of treatment with methotrexate in patients with early inflammatory polyarthritis? Ann Rheum Dis (2008) 0.97
Traditional cardiovascular risk factors measured prior to the onset of inflammatory polyarthritis. Rheumatology (Oxford) (2004) 0.96
Association between socioeconomic status, learned helplessness, and disease outcome in patients with inflammatory polyarthritis. Arthritis Care Res (Hoboken) (2012) 0.91
Association of morbid obesity with disability in early inflammatory polyarthritis: results from the Norfolk Arthritis Register. Arthritis Care Res (Hoboken) (2013) 0.91
Risk of lymphoma in patients with RA treated with anti-TNFalpha agents. Ann Rheum Dis (2005) 0.90
Developments in rheumatology consultant manpower provision: the BSR/arc Workforce Register 2003-05. Rheumatology (Oxford) (2006) 0.85
Lymphoma and rheumatoid arthritis--again. Rheumatology (Oxford) (2006) 0.85
The NOAR Damaged Joint Count (NOAR-DJC): a clinical measure for assessing articular damage in patients with early inflammatory polyarthritis including rheumatoid arthritis. Rheumatology (Oxford) (2004) 0.82
The relationship between post-onset pregnancy and functional outcome in women with recent onset inflammatory polyarthritis: results from the Norfolk Arthritis Register. Ann Rheum Dis (2010) 0.80
Parity, time since last live birth and long-term functional outcome: a study of women participating in the Norfolk Arthritis Register. Ann Rheum Dis (2011) 0.79
The role of specialists in managing established rheumatoid arthritis. Rheumatology (Oxford) (2008) 0.78
The overall status in rheumatoid arthritis (OSRA) measure--further evidence to support its use in clinical practice. Rheumatology (Oxford) (2007) 0.78
The relationship between oral contraceptive use and functional outcome in women with recent-onset inflammatory polyarthritis: results from the Norfolk Arthritis Register. Arthritis Rheum (2011) 0.78
Self-reported pain severity is associated with a history of coronary heart disease. Eur J Pain (2014) 0.76
An update on UK rheumatology consultant workforce provision: the BSR/ARC Workforce Register 2005-07: assessing the impact of recent changes in NHS provision. Rheumatology (Oxford) (2008) 0.75
Multiple adverse pregnancy outcomes before symptom onset are associated with a worse disease outcome in women with recent-onset inflammatory polyarthritis. Ann Rheum Dis (2011) 0.75